Trial Profile
Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Karyopharm Therapeutics
- 10 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 12 Dec 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 28 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.